Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

NCT01701401 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

870

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG: LDV/SOF
DRUG: RBV

Sponsor

Gilead Sciences